Key clinical point: Higher out-of-pocket costs for oral tyrosine kinase inhibitors were linked to inferior survival in patients with advanced, biomarker-positive non–small cell lung cancer.
Major finding: Patients in the high-cost quartile were 2.31 times as likely to die as patients in the lower quartiles, according to results of a multivariable analysis.
Study details: A retrospective study including data on 106 patients with EGFR- and ALK-positive stage IV non–small cell lung cancer in the Washington Surveillance, Epidemiology, and End Results registry who had at least one oral tyrosine kinase inhibitors prescription.
Disclosures: Funding for the study came from the National Institutes of Health. Dr. Goulart reported disclosures related to Flatiron Health (travel, accommodations, and expenses).
Goulart BHL et al. QCS 2019, Abstract 3.